Integrated Pharmaceuticals, Inc. (INTP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Integrated Pharmaceuticals, Inc. (INTP) trades at $0.000001 with AI Score 46/100 (Grade C). Integrated Pharmaceuticals, Inc. (INTP) develops and produces specialty chemicals and nutraceuticals, including calcium supplements and recombinant DNA technology-derived products. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for INTP: INTP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INTP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INTP: 1/2 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Integrated Pharmaceuticals, Inc. (INTP) Healthcare & Pipeline Overview
Integrated Pharmaceuticals, Inc. specializes in developing and producing specialty chemicals and nutraceuticals for human, plant, and animal applications, alongside advanced recombinant DNA technologies. Based in Fitchburg, Massachusetts, the company distributes its diverse product portfolio, including calcium supplements, through established retail and distribution networks within the healthcare sector.
What Is the Investment Thesis for INTP?
Integrated Pharmaceuticals, Inc. (INTP) operates in the niche markets of specialty chemicals and nutraceuticals, offering compounds with proven therapeutic value and developing advanced recombinant DNA technologies. The company's diversified product portfolio, including calcium supplements for consumer goods, leverages a distribution and retail network for market access. Potential value drivers include the ongoing demand for specialized ingredients in healthcare and food sectors, and the long-term prospects of its recombinant DNA technology development. However, the investment thesis is significantly overshadowed by substantial risks, including an extremely low market capitalization of $1,787, a beta of 5.37 indicating high volatility, and its listing on the OTC Other tier with unknown disclosure status. The company's minimal operational scale, with only four employees, further highlights the inherent financial distress and operational challenges, necessitating close monitoring of its ability to sustain operations and meet regulatory obligations.
Based on FMP financials and quantitative analysis
INTP Key Highlights
Market Capitalization: $1,787, reflecting an extremely micro-cap valuation and significant financial distress.
- Beta: 5.37, indicating very high volatility and sensitivity to market movements compared to the broader market.
- Employee Base: Operates with only 4 employees, suggesting a minimal operational footprint and highly lean structure.
- Product Focus: Engaged in the development and production of specialty chemicals and nutraceuticals for human, plant, and animal applications.
- Technological Scope: Actively develops technologies for clinically active pharmaceutical compounds, including recombinant DNA technology-derived products.
Who Are INTP's Competitors?
INTP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INTP's Key Strengths?
Diverse product portfolio spanning specialty chemicals, nutraceuticals, and calcium supplements.
- Engagement in advanced recombinant DNA technology development for pharmaceutical compounds.
- Established distribution and retail network for product sales in the U.S.
- Long corporate history, incorporated in 1969, suggesting foundational experience.
What Are INTP's Weaknesses?
Extremely low market capitalization of $1,787, indicating significant financial distress.
- Minimal operational scale with only 4 employees, limiting capacity and resources.
- Listing on the OTC Other tier, suggesting limited investor confidence and transparency.
- Unknown disclosure status, hindering investor access to financial information.
What Could Drive INTP Stock Higher?
INTP catalyst: Successful development and patenting of a novel compound or technology derived from its recombinant DNA efforts, potentially attracting partnerships or licensing agreements.
- Expansion of its distribution network, leading to increased market penetration and sales volume for its specialty chemicals and nutraceuticals.
- Introduction of new calcium supplement formulations or fortified beverage products that gain significant traction in the consumer market, driving revenue growth.
- Any verifiable improvement in financial disclosure or reporting status, which could enhance investor confidence and market visibility.
- Securing a significant supply contract for its specialty chemicals with a larger pharmaceutical or food industry player, providing stable revenue streams.
What Are the Key Risks for INTP?
The company's extremely low market capitalization of $1,787 and share price of $0.00 indicate severe financial distress and potential for operational insolvency.
- Minimal operational scale with only 4 employees raises concerns about capacity for R&D, manufacturing, and market expansion.
- Significant regulatory hurdles and compliance costs inherent in the pharmaceutical and nutraceutical industries, which could strain limited resources.
- Intense competition from larger, well-established companies in both the specialty chemicals and nutraceutical markets, making market share gains challenging.
- Listing on the OTC Other tier with an 'Unknown' disclosure status poses substantial transparency risks and limits investor access to critical financial and operational information.
What Are the Growth Opportunities for INTP?
- **Expanding Nutraceutical Market Penetration:** The global nutraceutical market is experiencing robust growth, driven by increasing consumer demand for health-enhancing food and dietary supplements. Integrated Pharmaceuticals, Inc. offers compounds and nutraceuticals with proven therapeutic or nutritional value. By strategically expanding its product line and distribution channels within this growing market, INTP could capture a larger share. The market for nutraceuticals is projected to continue its upward trajectory, offering a long-term opportunity for companies with specialized ingredients and effective market access, potentially through new distributor partnerships or increased retail presence for its existing offerings like calcium supplements.
- **Leveraging Specialty Chemicals for Pharmaceutical Applications:** Integrated Pharmaceuticals develops and produces specialty chemicals, including active small molecules, which are critical components in the pharmaceutical industry. The demand for high-quality, specialized chemical intermediates and active pharmaceutical ingredients (APIs) remains strong, driven by new drug development and manufacturing needs. By focusing on unique or difficult-to-synthesize compounds, INTP could carve out a valuable niche. This opportunity involves securing supply contracts with larger pharmaceutical manufacturers or research institutions, capitalizing on the stringent quality requirements and specialized expertise needed in this segment, which typically offers higher margins for proprietary or complex chemical entities.
- **Advancement in Recombinant DNA Technology:** The company is involved in developing technologies for recombinant DNA-derived products, a cutting-edge field with immense potential in biopharmaceuticals. This area includes the production of therapeutic proteins, vaccines, and gene therapies, representing a multi-billion-dollar market with significant growth prospects. Successful development and commercialization of even a single clinically active compound using this technology could be transformative for INTP. This growth opportunity is long-term and high-risk, requiring substantial R&D investment and navigating complex regulatory pathways, but offers the potential for high-value intellectual property and market exclusivity.
- **Growth in Fortified Food and Beverage Market:** Integrated Pharmaceuticals offers calcium supplements used in a wide array of consumer products, including soft drinks, coffee, tea, soup, dehydrated sauces, and fortified bottled water. The market for functional foods and beverages, where products are enhanced with additional health benefits, is a significant and expanding segment. By innovating new supplement formulations or securing additional partnerships with major food and beverage manufacturers, INTP could significantly increase its revenue from this product line. This strategy involves understanding consumer trends in health-conscious eating and drinking, and adapting product offerings to meet evolving market demands for nutritional fortification.
- **Optimizing and Expanding Distribution and Retail Networks:** The company currently sells its products through distributors and retailers. A key growth opportunity lies in optimizing these existing channels and strategically expanding into new ones. This could involve identifying underserved geographic markets, partnering with new types of retailers (e.g., health food stores, online pharmacies), or enhancing relationships with current distributors to increase product placement and sales volume. A more robust and efficient distribution network can significantly improve market reach for both specialty chemicals and consumer-facing nutraceuticals, leading to increased sales and brand visibility without necessarily requiring extensive internal sales infrastructure development.
What Threats Does INTP Face?
- Intense competition from larger, better-funded pharmaceutical and chemical manufacturers.
- Significant regulatory hurdles and compliance costs in the pharmaceutical and nutraceutical industries.
- Capital constraints limiting R&D investment and market expansion efforts.
- Risk of delisting or inability to maintain operations due to financial distress.
What Are INTP's Competitive Advantages?
- Specialized product portfolio in nutraceuticals and specialty chemicals with proven therapeutic value.
- Proprietary development in recombinant DNA technology for clinically active pharmaceutical compounds.
- Established distribution and retail channels for market access in the United States.
- Long operational history since 1969, potentially indicating accumulated expertise in its niche areas.
What Does INTP Do?
Integrated Pharmaceuticals, Inc. (INTP), incorporated in 1969 and headquartered in Fitchburg, Massachusetts, has evolved significantly since its inception, having formerly operated as Digital Caddies, Inc. before rebranding in September 2011. The company's core business revolves around the development and production of specialty chemicals and nutraceuticals within the United States. Its product offerings are diverse, encompassing compounds and nutraceuticals recognized for their therapeutic or nutritional value across human, plant, and animal applications. This includes a focus on active small molecules and advanced recombinant DNA technology-derived products, indicating a commitment to innovation in pharmaceutical compounds. Beyond these specialized areas, Integrated Pharmaceuticals also manufactures calcium supplements, which are designed for integration into a variety of consumer products such as soft drinks, coffee, tea, soup, dehydrated sauces, and beverages, including fortified bottled water. The company leverages a network of distributors and retailers to bring its products to market, aiming to reach a broad customer base. Despite its long history and diverse product portfolio, INTP currently operates with a very small team of four employees, reflecting a highly focused or distressed operational model. Its strategic positioning in both specialty chemicals and the growing nutraceutical market, coupled with its foray into recombinant DNA technology, defines its unique profile within the broader healthcare sector.
What Products and Services Does INTP Offer?
- Develops and produces specialty chemicals for various applications.
- Manufactures nutraceuticals with therapeutic or nutritional value for humans, plants, and animals.
- Engages in the development of technologies for clinically active pharmaceutical compounds.
- Focuses on active small molecules within its pharmaceutical compound development.
- Utilizes recombinant DNA technology for product development.
- Produces calcium supplements for integration into soft drinks, coffee, tea, soup, and other beverages.
- Offers calcium-fortified bottled water.
- Sells its products through a network of distributors and retailers in the United States.
How Does INTP Make Money?
- Research and development of specialty chemicals and advanced pharmaceutical technologies.
- Manufacturing and production of nutraceuticals and calcium supplements.
- Sales of proprietary compounds and products through a business-to-business model via distributors.
- Retail sales of consumer-facing products like fortified beverages through retail channels.
What Industry Does INTP Operate In?
Integrated Pharmaceuticals, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, a segment of the broader healthcare sector characterized by diverse product development and manufacturing. This industry includes companies focused on niche chemical compounds, nutraceuticals, and specialized pharmaceutical ingredients. The market for specialty chemicals, particularly those with therapeutic applications, is driven by demand from various industries, including pharmaceuticals, food and beverage, and agriculture. The nutraceutical market, encompassing products with health benefits beyond basic nutrition, is experiencing consistent growth due to increasing consumer awareness of health and wellness. INTP's dual focus positions it to potentially capitalize on these trends, although its current operational scale and financial status suggest it occupies a very small, highly specialized, and potentially distressed segment of this competitive landscape. The development of recombinant DNA technology further places it in a high-growth, high-innovation area, albeit with significant capital and regulatory requirements typical of advanced drug development.
Who Are INTP's Key Customers?
- Pharmaceutical companies requiring specialty chemicals and active small molecules.
- Food and beverage manufacturers seeking calcium supplements for product fortification.
- Distributors and retailers who stock and sell the company's nutraceuticals and fortified products.
- Agricultural and animal health sectors utilizing compounds with therapeutic or nutritional value for plants and animals.
How Integrated Pharmaceuticals, Inc. Is Valued
Relative to its peer group, INTP's quantitative score of 46/100 is below the peer average of 62/100.
Company Profile
Integrated Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Fitchburg, US. The company is led by CEO David H. Smith II. INTP has traded publicly since 2000.
INTP Financials
Bull Case vs Bear Case
Bull Case
- Insiders seem confident, buying shares recently, which often signals belief in the company's future prospects.
- The community's generally optimistic, buzzing about potential new drug approvals.
- Perception is shifting – more analysts are highlighting INTP's innovative pipeline.
- Recent market developments suggest increased investor appetite for biotech, benefiting companies like INTP.
Bear Case
- Some insiders are selling too, possibly to rebalance portfolios or take profits, creating uncertainty.
- A vocal segment of the community worries about potential regulatory hurdles for their key drug candidate.
- Market perception is mixed; some see INTP as overvalued compared to peers.
- Recent market volatility has made investors risk-averse, potentially impacting INTP's stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
INTP Latest News
No recent news available for INTP.
INTP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INTP.
Price Targets
Wall Street price target analysis for INTP.
INTP MoonshotScore
What does this score mean?
The MoonshotScore rates INTP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David H. Smith II
Managing Director
David H. Smith II serves as the managing director for Integrated Pharmaceuticals, Inc., overseeing a lean team of four employees. His leadership is crucial for a company operating in the specialized fields of chemicals and nutraceuticals, particularly given its small scale and unique market position. While specific details on his prior career history, education, or previous roles are not provided in the available data, his current role places him at the helm of a company with a long operational history and a focus on niche product development within the healthcare sector.
Track Record: Under David H. Smith II's management, Integrated Pharmaceuticals, Inc. continues to operate within its defined scope of developing specialty chemicals and nutraceuticals, including advanced recombinant DNA technology. His tenure is marked by the ongoing efforts to maintain the company's product offerings and distribution channels despite its extremely limited resources and market capitalization. Key achievements, strategic decisions, or specific company milestones directly attributable to his leadership are not detailed in the provided information.
INTP OTC Market Information
Integrated Pharmaceuticals, Inc. (INTP) trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and disclosure, OTC Other companies face minimal to no reporting standards. This tier is typically home to shell companies, defunct entities, or companies with severe financial distress, often characterized by extremely low share prices and limited public information. It signifies a high-risk environment for investors due to the lack of transparency and regulatory oversight compared to higher OTC tiers like OTCQB or OTCQX.
- OTC Tier: OTC Other
- Extreme lack of transparency due to 'Unknown' disclosure status, making fundamental analysis nearly impossible.
- High susceptibility to price manipulation and fraud given the minimal regulatory oversight of the OTC Other tier.
- Significant illiquidity, leading to wide bid-ask spreads and difficulty in executing trades at fair prices.
- Potential for complete loss of investment due to the company's severe financial distress and minimal operational capacity.
- Limited access to capital markets for funding, hindering any potential growth or operational stability.
- Verify any available financial statements directly from the company or state filings, if accessible.
- Research any recent news releases or corporate actions, scrutinizing the source and veracity.
- Attempt to contact investor relations (if available) for clarification on disclosure status and operations.
- Assess the company's legal and regulatory standing, checking for any outstanding litigation or enforcement actions.
- Investigate the background and track record of current management beyond what is publicly stated.
- Analyze the company's product pipeline and market potential, assuming any claims are verifiable.
- Evaluate the company's ability to generate revenue and maintain operations given its minimal employee count and market cap.
- Incorporated in 1969, indicating a long-standing corporate existence, albeit with a name change.
- Maintains a physical headquarters in Fitchburg, Massachusetts, suggesting a tangible presence.
- Engaged in specific business activities: developing specialty chemicals, nutraceuticals, and recombinant DNA technology.
- Has a named managing director, David H. Smith II, providing a point of leadership.
- Sells products through distributors and retailers, implying some level of commercial activity.
What Investors Ask About Integrated Pharmaceuticals, Inc. (INTP) — Healthcare
What does the AI Score mean for INTP?
INTP holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Integrated Pharmaceuticals, Inc. (INTP) develops and produces specialty chemicals and nutraceuticals, including calcium supplements and recombinant DNA technology-derived products. The company …
What does Integrated Pharmaceuticals, Inc. do?
Integrated Pharmaceuticals, Inc. is a U.S.-based company focused on the development and production of specialty chemicals and nutraceuticals. Its product portfolio includes compounds and nutraceuticals with proven therapeutic or nutritional value for humans, plants, and animals. The company also invests in developing technologies for clinically active pharmaceutical compounds, specifically active small molecules and products derived from recombinant DNA technology.
How does Integrated Pharmaceuticals, Inc. position itself within the specialty chemicals and nutraceuticals market?
Integrated Pharmaceuticals, Inc. positions itself by offering a dual focus on specialized ingredients for both the healthcare and consumer sectors. In specialty chemicals, it targets the need for active small molecules and advanced pharmaceutical compounds, including those developed through recombinant DNA technology. This places it in a niche area requiring scientific expertise.
What are the primary operational and financial risks associated with investing in Integrated Pharmaceuticals, Inc.?
Investing in Integrated Pharmaceuticals, Inc. carries substantial operational and financial risks. Operationally, the company's minimal employee base of just four individuals suggests very limited capacity for research, development, manufacturing, and market expansion, potentially hindering its ability to compete effectively or scale.
What are the key factors to evaluate for INTP?
Integrated Pharmaceuticals, Inc. (INTP) holds an AI score of 46/100 (low). (INTP) operates in the niche markets of specialty chemicals and nutraceuticals, offering compounds with proven therapeutic value and developing advanced recombinant DNA technologies. Not financial advice.
How frequently does INTP data refresh on this page?
INTP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven INTP's recent stock price performance?
Integrated Pharmaceuticals, Inc. (INTP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio spanning specialty chemicals, nutraceuticals, and calcium supplements. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INTP overvalued or undervalued right now?
Integrated Pharmaceuticals, Inc. (INTP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research INTP before investing?
Before investing in Integrated Pharmaceuticals, Inc. (INTP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available, especially regarding revenue, profitability, and specific market share.
- Growth opportunities and competitive advantages are inferred from the company's stated business activities and industry trends, rather than specific company-provided projections.
- The 'Unknown' disclosure status for the OTC listing significantly impacts the depth of analysis possible for financial health and operational specifics.
- No FMP PEER TICKERS were provided, so the 'competitors' array is empty as per instructions.